Noh, J. Y., Jeong, H. W. & Shin, E. C. SARS-CoV-2 mutations, vaccines, and immunity: implication of variants of concern. Sign Transduct. Goal. Ther. 6, 203 (2021).
Andrews, N. et al. Covid-19 vaccine effectiveness towards the omicron (B.1.1.529) variant. New Engl. J. Med. 386, 1532–1546 (2022).
Geers, D. et al. SARS-CoV-2 variants of concern partially escape humoral however not T-cell responses in COVID-19 convalescent donors and vaccinees. Sci. Immunol. 6, eabj1750 (2021).
Nasreen, S. et al. Effectiveness of COVID-19 vaccines towards symptomatic SARS-CoV-2 an infection and extreme outcomes with variants of concern in Ontario. Nat. Microbiol. 7, 379–385 (2022).
Wratil, P. R. et al. Three exposures to the spike protein of SARS-CoV-2 by both an infection or vaccination elicit superior neutralizing immunity to all variants of concern. Nat. Med. 28, 496–503 (2022).
Sakurai, A. et al. Pure historical past of asymptomatic SARS-CoV-2 an infection. New Engl. J. Med. 383, 885–886 (2020).
Spudich, S. & Nath, A. Nervous system penalties of COVID-19. Science 375, 267–269 (2022).
Xie, Y., Bowe, B. & Al-Aly, Z. Burdens of post-acute sequelae of COVID-19 by severity of acute an infection, demographics and well being standing. Nat. Commun. 12, 6571 (2021).
Xie, Y., Xu, E., Bowe, B. & Al-Aly, Z. Lengthy-term cardiovascular outcomes of COVID-19. Nat. Med. 28, 583–590 (2022).
Guan, W. J. et al. Medical traits of coronavirus illness 2019 in China. New Engl. J. Med. 382, 1708–1720 (2020).
Al-Aly, Z., Xie, Y. & Bowe, B. Excessive-dimensional characterization of post-acute sequelae of COVID-19. Nature 594, 259–264 (2021).
Muscogiuri, G. et al. Low-grade irritation, CoVID-19, and weight problems: medical facet and molecular insights in childhood and maturity. Int. J. Obes. 46, 1254–1261 (2022).
Ng, W. H. et al. Comorbidities in SARS-CoV-2 sufferers: a scientific overview and meta-analysis. mBio 12, e03647–20 (2021).
Value-Haywood, E. G., Burton, J., Fort, D. & Seoane, L. Hospitalization and mortality amongst black sufferers and white sufferers with Covid-19. New Engl. J. Med. 382, 2534–2543 (2020).
O’Driscoll, M. et al. Age-specific mortality and immunity patterns of SARS-CoV-2. Nature 590, 140–145 (2021).
Klang, E. et al. Extreme weight problems as an impartial threat issue for covid-19 mortality in hospitalized sufferers youthful than 50. Weight problems (Silver Spring) 28, 1595–1599 (2020).
Jin, J. M. et al. Gender variations in sufferers with COVID-19: deal with severity and mortality. Entrance. Public Well being 8, 152 (2020).
Mateus, J. et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed people. Science 370, 89–94 (2020).
Dykema, A. G. et al. Purposeful characterization of CD4+ T cell receptors crossreactive for SARS-CoV-2 and endemic coronaviruses. J. Clin. Make investments. 131, e146922 (2021).
Woldemeskel, B. A. et al. CD4+ T cells from COVID-19 mRNA vaccine recipients acknowledge a conserved epitope current in numerous coronaviruses. J. Clin. Make investments. 132, e156083 (2022).
Le Bert, N. et al. SARS-CoV-2-specific T cell immunity in circumstances of COVID-19 and SARS, and uninfected controls. Nature 584, 457–462 (2020).
Tan, H. X. et al. Adaptive immunity to human coronaviruses is widespread however low in magnitude. Clin. Transl. Immunol. 10, e1264 (2021).
Grifoni, A. et al. Targets of T cell responses to SARS-CoV-2 coronavirus in people with COVID-19 illness and unexposed people. Cell 181, 1489–1501.e1415 (2020).
Ni, L. et al. Detection of SARS-CoV-2-specific humoral and mobile immunity in COVID-19 convalescent people. Immunity 52, 971–977.e973 (2020).
Peng, Y. et al. Broad and robust reminiscence CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent people following COVID-19. Nat. Immunol. 21, 1336–1345 (2020).
Weiskopf, D. et al. Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 sufferers with acute respiratory misery syndrome. Sci. Immunol. 5, eabd2071 (2020).
Kundu, R. et al. Cross-reactive reminiscence T cells affiliate with safety towards SARS-CoV-2 an infection in COVID-19 contacts. Nat. Commun. 13, 80 (2022).
Lineburg, Ok. E. et al. CD8(+) T cells particular for an immunodominant SARS-CoV-2 nucleocapsid epitope cross-react with selective seasonal coronaviruses. Immunity 54, 1055–1065.e1055 (2021).
Braun, J. et al. SARS-CoV-2-reactive T cells in wholesome donors and sufferers with COVID-19. Nature 587, 270–274 (2020).
Garcia-Jimenez, A. F. et al. Cross-reactive mobile, however not humoral, immunity is detected between OC43 and SARS-CoV-2 NPs in folks not contaminated with SARS-CoV-2: Attainable position of cT(FH) cells. J. Leukoc. Biol. 112, 339–346 (2022).
Westphal, T. et al. Proof for broad cross-reactivity of the SARS-CoV-2 NSP12-directed CD4(+) T-cell response with pre-primed responses directed towards widespread chilly coronaviruses. Entrance. Immunol. 14, 1182504 (2023).
Diniz, M. O. et al. Airway-resident T cells from unexposed people cross-recognize SARS-CoV-2. Nat. Immunol. 23, 1324–1329 (2022).
Mesel-Lemoine, M. et al. A human coronavirus answerable for the widespread chilly massively kills dendritic cells however not monocytes. J. Virol. 86, 7577–7587 (2012).
Gorse, G. J., Patel, G. B., Vitale, J. N. & O’Connor, T. Z. Prevalence of antibodies to 4 human coronaviruses is decrease in nasal secretions than in serum. Clin. Vaccine Immunol. 17, 1875–1880 (2010).
Ellis, P., Somogyvari, F., Virok, D. P., Noseda, M. & McLean, G. R. Decoding Covid-19 with the SARS-CoV-2 Genome. Curr. Genet. Med. Rep. 9, 1–12 (2021).
Loyal, L. et al. Cross-reactive CD4(+) T cells improve SARS-CoV-2 immune responses upon an infection and vaccination. Science 374, eabh1823 (2021).
Mateus, J. et al. Low-dose mRNA-1273 COVID-19 vaccine generates sturdy reminiscence enhanced by cross-reactive T cells. Science374, eabj9853 (2021).
Bacher, P. et al. Low-avidity CD4(+) T cell responses to SARS-CoV-2 in unexposed people and people with extreme COVID-19. Immunity 53, 1258–1271.e1255 (2020).
Augusto, D. G. et al. A standard allele of HLA is related to asymptomatic SARS-CoV-2 an infection. Nature 620, 128–136 (2023).
Gouma, S. et al. Well being care employee seromonitoring reveals complicated relationships between widespread coronavirus antibodies and COVID-19 symptom period. JCI Perception 6, e150449 (2021).
Mallajosyula, V. et al. CD8(+) T cells particular for conserved coronavirus epitopes correlate with milder illness in COVID-19 sufferers. Sci. Immunol. 6, eabg5669 (2021).
Bonifacius, A. et al. COVID-19 immune signatures reveal secure antiviral T cell operate regardless of declining humoral responses. Immunity 54, 340–354.e346 (2021).
Zellweger, R. M., Prestwood, T. R. & Shresta, S. Enhanced an infection of liver sinusoidal endothelial cells in a mouse mannequin of antibody-induced extreme dengue illness. Cell Host Microbe 7, 128–139 (2010).
Zellweger, R. M. et al. CD8+ T cells can mediate short-term safety towards heterotypic dengue virus reinfection in mice. J. Virol. 89, 6494–6505 (2015).
Balsitis, S. J. et al. Deadly antibody enhancement of dengue illness in mice is prevented by Fc modification. PLoS Pathog. 6, e1000790 (2010).
Wen, J. et al. Dengue virus-reactive CD8(+) T cells mediate cross-protection towards subsequent Zika virus problem. Nat. Commun. 8, 1459 (2017).
Wen, J. et al. CD4(+) T cells cross-reactive with dengue and zika viruses shield towards zika virus an infection. Cell Rep. 31, 107566 (2020).
Regla-Nava, J. A. et al. Cross-reactive Dengue virus-specific CD8(+) T cells shield towards Zika virus throughout being pregnant. Nat. Commun. 9, 3042 (2018).
Katzelnick, L. C. et al. Zika virus an infection enhances future threat of extreme dengue illness. Science 369, 1123–1128 (2020).
Katzelnick, L. C. et al. Antibody-dependent enhancement of extreme dengue illness in people. Science358, 929–932 (2017).
Salje, H. et al. Reconstruction of antibody dynamics and an infection histories to guage dengue threat. Nature 557, 719–723 (2018).
Fowler, A. M. et al. Maternally acquired zika antibodies improve dengue illness severity in mice. Cell Host Microbe 24, 743–750.e745 (2018).
Gordon, A. et al. Prior dengue virus an infection and threat of Zika: a pediatric cohort in Nicaragua. PLoS Med. 16, e1002726 (2019).
Rodriguez-Barraquer, I. et al. Impression of preexisting dengue immunity on Zika virus emergence in a dengue endemic area. Science 363, 607–610 (2019).
Pedroso, C. et al. Cross-protection of dengue virus an infection towards congenital zika syndrome, Northeastern Brazil. Emerg. Infect. Dis. 25, 1485–1493 (2019).
Sridhar, S. et al. Impact of dengue serostatus on dengue vaccine security and efficacy. New Engl. J. Med. 379, 327–340 (2018).
Sharp, T. M. et al. Information gaps within the epidemiology of extreme dengue impede vaccine analysis. Lancet Infect. Dis. 22, e42–e51 (2022).
Katzelnick, L. C., Bos, S. & Harris, E. Protecting and enhancing interactions amongst dengue viruses 1-4 and Zika virus. Curr. Opin. Virol. 43, 59–70 (2020).
Valentine, Ok. M., Croft, M. & Shresta, S. Safety towards dengue virus requires a sustained stability of antibody and T cell responses. Curr. Opin. Virol. 43, 22–27 (2020).
Ngono, A. E. & Shresta, S. Immune response to dengue and zika. Annu. Rev. Immunol. 36, 279–308 (2018).
Hassert, M., Brien, J. D. & Pinto, A. Ok. Mouse fashions of heterologous flavivirus immunity: a job for cross-reactive T cells. Entrance. Immunol. 10, 1045 (2019).
Gonzalez-Galarza, F. F. et al. Allele frequency web database (AFND) 2020 replace: gold-standard knowledge classification, open entry genotype knowledge and new question instruments. Nucleic Acids Res. 48, D783–D788 (2020).
Solberg, O. D. et al. Balancing choice and heterogeneity throughout the classical human leukocyte antigen loci: a meta-analytic overview of 497 inhabitants research. Hum. Immunol. 69, 443–464 (2008).
Bastard, P. et al. Autoantibodies neutralizing sort I IFNs are current in ~4% of uninfected people over 70 years outdated and account for ~20% of COVID-19 deaths. Sci. Immunol. 6, eabl4340 (2021).
Bastard, P. et al. Autoantibodies towards sort I IFNs in sufferers with life-threatening COVID-19. Science 370, eabd4585 (2020).
Koning, R., Bastard, P., Casanova, J. L., Brouwer, M. C. & van de Beek, D. with the Amsterdam UMCC-BI. Autoantibodies towards sort I interferons are related to multi-organ failure in COVID-19 sufferers. Intensive Care Med. 47, 704–706 (2021).
Troya, J. et al. Neutralizing autoantibodies to sort I IFNs in >10% of sufferers with extreme COVID-19 pneumonia hospitalized in Madrid, Spain. J. Clin. Immunol. 41, 914–922 (2021).
Vazquez, S. E. et al. Neutralizing autoantibodies to sort I interferons in COVID-19 convalescent donor plasma. J. Clin. Immunol. 41, 1169–1171 (2021).
Wang, E. Y. et al. Various purposeful autoantibodies in sufferers with COVID-19. Nature 595, 283–288 (2021).
Zhang, Q. et al. Inborn errors of sort I IFN immunity in sufferers with life-threatening COVID-19. Science 370, eabd4570 (2020).
Elong Ngono, A. et al. Protecting position of cross-reactive CD8 T cells towards dengue virus an infection. EBioMedicine 13, 284–293 (2016).
Weiskopf, D. et al. Immunodominance modifications as a operate of the infecting dengue virus serotype and first versus secondary an infection. J. Virol. 88, 11383–11394 (2014).
Weiskopf, D. et al. Insights into HLA-restricted T cell responses in a novel mouse mannequin of dengue virus an infection level towards new implications for vaccine design. J. Immunol. 187, 4268–4279 (2011).
Wen, J. et al. Identification of Zika virus epitopes reveals immunodominant and protecting roles for dengue virus cross-reactive CD8(+) T cells. Nat. Microbiol. 2, 17036 (2017).
Vita, R. et al. The Immune Epitope Database (IEDB): 2018 replace. Nucleic Acids Res. 47, D339–D343 (2019).
Leist, S. R. et al. A mouse-adapted SARS-CoV-2 induces acute lung damage and mortality in normal laboratory mice. Cell 183, 1070–1085.e1012 (2020).
Liu, Y. et al. The N501Y spike substitution enhances SARS-CoV-2 an infection and transmission. Nature 602, 294–299 (2022).
Pan, T. et al. An infection of wild-type mice by SARS-CoV-2 B.1.351 variant signifies a attainable novel cross-species transmission route. Sign Transduct. Goal Ther. 6, 420 (2021).
Ferretti, A. P. et al. Unbiased screens present CD8(+) T cells of COVID-19 sufferers acknowledge shared epitopes in SARS-CoV-2 that largely reside outdoors the spike protein. Immunity 53, 1095–1107.e1093 (2020).
Nguyen, T. H. O. et al. CD8(+) T cells particular for an immunodominant SARS-CoV-2 nucleocapsid epitope show excessive naive precursor frequency and TCR promiscuity. Immunity 54, 1066–1082.e1065 (2021).
Schulien, I. et al. Characterization of pre-existing and induced SARS-CoV-2-specific CD8(+) T cells. Nat. Med. 27, 78–85 (2021).
Sekine, T. et al. Sturdy T cell immunity in convalescent people with asymptomatic or gentle COVID-19. Cell 183, 158–168.e114 (2020).
Painter, M. M. et al. Speedy induction of antigen-specific CD4(+) T cells is related to coordinated humoral and mobile immunity to SARS-CoV-2 mRNA vaccination. Immunity 54, 2133–2142.e2133 (2021).
Dan, J. M. et al. Immunological reminiscence to SARS-CoV-2 assessed for as much as 8 months after an infection. Science 371, eabf4063 (2021).
Hicks, J. et al. Serologic cross-reactivity of SARS-CoV-2 with endemic and seasonal betacoronaviruses. J. Clin. Immunol. 41, 906–913 (2021).
Saletti, G. et al. Older adults lack SARS CoV-2 cross-reactive T lymphocytes directed to human coronaviruses OC43 and NL63. Sci. Rep. 10, 21447 (2020).
Nickbakhsh, S. et al. Epidemiology of seasonal coronaviruses: establishing the context for the emergence of coronavirus illness 2019. J. Infect. Dis. 222, 17–25 (2020).
Killerby, M. E. et al. Human coronavirus circulation in the US 2014-2017. J. Clin. Virol. 101, 52–56 (2018).
Snyder, T. M. et al. Magnitude and dynamics of the T-cell response to SARS-CoV-2 an infection at each particular person and inhabitants ranges. medRxiv https://doi.org/10.1101/2020.07.31.20165647 (2020).
Tarke, A. et al. Complete evaluation of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 circumstances. Cell Rep. Med. 2, 100204 (2021).
Saini, S. Ok. et al. SARS-CoV-2 genome-wide T cell epitope mapping reveals immunodominance and substantial CD8(+) T cell activation in COVID-19 sufferers. Sci. Immunol. 6, eabf7550 (2021).
Quadeer, A. A., Ahmed, S. F. & McKay, M. R. Panorama of epitopes focused by T cells in 852 people recovered from COVID-19: Meta-analysis, immunoprevalence, and internet platform. Cell reviews. Drugs 2, 100312 (2021).
Nelde, A. et al. SARS-CoV-2-derived peptides outline heterologous and COVID-19-induced T cell recognition. Nat. Immunol. 22, 74–85 (2021).
Grifoni, A. et al. A sequence homology and bioinformatic strategy can predict candidate targets for immune responses to SARS-CoV-2. Cell Host Microbe 27, 671–680.e672 (2020).
Kared, H. et al. SARS-CoV-2-specific CD8+ T cell responses in convalescent COVID-19 people. J. Clin. Make investments. 131, e145476 (2021).
Ng, O. W. et al. Reminiscence T cell responses focusing on the SARS coronavirus persist as much as 11 years post-infection. Vaccine 34, 2008–2014 (2016).
Prakash, S. et al. Genome-wide B cell, CD4(+), and CD8(+) T cell epitopes which can be extremely conserved between human and animal coronaviruses, recognized from SARS-CoV-2 as targets for preemptive pan-coronavirus vaccines. J. Immunol. 206, 2566–2582 (2021).
Shen, Y et al. Ancestral origins are related to SARS-CoV-2 susceptibility and safety in a Florida affected person inhabitants. bioRxiv https://doi.org/10.1101/2022.03.30.486345 (2022).
Keller, M. D. et al. SARS-CoV-2-specific T cells are quickly expanded for therapeutic use and goal conserved areas of the membrane protein. Blood 136, 2905–2917 (2020).
Tan, A. T. et al. Early induction of purposeful SARS-CoV-2-specific T cells associates with speedy viral clearance and gentle illness in COVID-19 sufferers. Cell Rep. 34, 108728 (2021).
Crotty, S. T follicular helper cell differentiation, operate, and roles in illness. Immunity 41, 529–542 (2014).
Ueno, H., Banchereau, J. & Vinuesa, C. G. Pathophysiology of T follicular helper cells in people and mice. Nat Immunol. 16, 142–152 (2015).
Heide, J. et al. Broadly directed SARS-CoV-2-specific CD4+ T cell response contains regularly detected peptide specificities throughout the membrane and nucleoprotein in sufferers with acute and resolved COVID-19. PLoS Pathog. 17, e1009842 (2021).
Karsten, H. et al. Excessive-resolution evaluation of particular person spike peptide-specific CD4(+) T-cell responses in vaccine recipients and COVID-19 sufferers. Clin. Transl. Immunol. 11, e1410 (2022).
Corey, L. et al. SARS-CoV-2 variants in sufferers with immunosuppression. New Engl. J. Med. 385, 562–566 (2021).
Redd, A. D. et al. CD8+ T-cell responses in COVID-19 convalescent people goal conserved epitopes from a number of outstanding SARS-CoV-2 circulating variants. Open Discussion board Infect. Dis. 8, ofab143 (2021).
Naranbhai, V. et al. T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most however not all people. Cell 185, 1041–1051.e1046 (2022).
Keeton, R. et al. T cell responses to SARS-CoV-2 spike cross-recognize Omicron. Nature 603, 488–492 (2022).
Gao, Y. et al. Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant. Nat. Med. 28, 472–476 (2022).
GeurtsvanKessel, C. H. et al. Divergent SARS-CoV-2 Omicron-reactive T and B cell responses in COVID-19 vaccine recipients. Sci. Immunol. 7, eabo2202 (2022).
Solar, J. et al. Technology of a broadly helpful mannequin for COVID-19 pathogenesis, vaccination, and therapy. Cell 182, 734–743.e735 (2020).
McMahan, Ok. et al. Correlates of safety towards SARS-CoV-2 in rhesus macaques. Nature 590, 630–634 (2021).
Soresina, A. et al. Two X-linked agammaglobulinemia sufferers develop pneumonia as COVID-19 manifestation however get better. Pediatr. Allergy Immunol. 31, 565–569 (2020).
Bange, E. M. et al. CD8(+) T cells contribute to survival in sufferers with COVID-19 and hematologic most cancers. Nat. Med. 27, 1280–1289 (2021).
Zhuang, Z. et al. Mapping and position of T cell response in SARS-CoV-2-infected mice. J. Exp. Med. 218, e20202187 (2021).
Israelow, B. et al. Adaptive immune determinants of viral clearance and safety in mouse fashions of SARS-CoV-2. Sci. Immunol. 6, eabl4509 (2021).
Rydyznski Moderbacher, C. et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and illness severity. Cell 183, 996–1012.e1019 (2020).
Nesterenko, P. A. et al. HLA-A(*)02:01 restricted T cell receptors towards the extremely conserved SARS-CoV-2 polymerase cross-react with human coronaviruses. Cell Rep. 37, 110167 (2021).
Le Bert, N. et al. Extremely purposeful virus-specific mobile immune response in asymptomatic SARS-CoV-2 an infection. J. Exp. Med. 218, e20202617 (2021).
Tan, C. C. S. et al. Pre-existing T cell-mediated cross-reactivity to SARS-CoV-2 can not solely be defined by prior publicity to endemic human coronaviruses. Infect. Genet. Evol. 95, 105075 (2021).
Eggenhuizen, P. J. et al. Heterologous immunity between SARS-CoV-2 and pathogenic micro organism. Entrance. Immunol. 13, 821595 (2022).
Low, J. S. et al. Clonal evaluation of immunodominance and cross-reactivity of the CD4 T cell response to SARS-CoV-2. Science 372, 1336–1341 (2021).
Sagar, M. et al. Current endemic coronavirus an infection is related to less-severe COVID-19. J. Clin. Make investments. 131, e143380 (2021).
Humbert, M. et al. Purposeful SARS-CoV-2 cross-reactive CD4(+) T cells established in early childhood decline with age. Proc. Natl Acad. Sci. USA 120, e2220320120 (2023).
Zhao, J. et al. Airway reminiscence CD4(+) T cells mediate protecting immunity towards rising respiratory coronaviruses. Immunity 44, 1379–1391 (2016).
Poston, D. et al. Absence of extreme acute respiratory syndrome coronavirus 2 neutralizing exercise in prepandemic sera from people with latest seasonal coronavirus an infection. Clin. Infect. Dis. 73, e1208–e1211 (2021).
Ercanoglu, M. S. et al. No substantial preexisting B cell immunity towards SARS-CoV-2 in wholesome adults. iScience 25, 103951 (2022).
Pinto, D. et al. Broad betacoronavirus neutralization by a stem helix-specific human antibody. Science 373, 1109–1116 (2021).
Solar, X. et al. Neutralization mechanism of a human antibody with pan-coronavirus reactivity together with SARS-CoV-2. Nat. Microbiol. 7, 1063–1074 (2022).
Dacon, C. et al. Broadly neutralizing antibodies goal the coronavirus fusion peptide. Science 377, 728–735 (2022).
Low, J. S. et al. ACE2-binding exposes the SARS-CoV-2 fusion peptide to broadly neutralizing coronavirus antibodies. Science 377, 735–742 (2022).
Anderson, E. M. et al. Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 an infection however not related to safety. Cell 184, 1858–1864.e1810 (2021).
Ng, Ok. W. et al. Preexisting and de novo humoral immunity to SARS-CoV-2 in people. Science 370, 1339–1343 (2020).
Poston, D et al. Absence of SARS-CoV-2 neutralizing exercise in pre-pandemic sera from people with latest seasonal coronavirus an infection. medRxiv https://doi.org/10.1101/2020.10.08.20209650 (2020).
Premkumar, L. et al. The receptor binding area of the viral spike protein is an immunodominant and extremely particular goal of antibodies in SARS-CoV-2 sufferers. Sci. Immunol. 5, eabc8413 (2020).
Grifoni, A. et al. Prior dengue virus publicity shapes T cell immunity to Zika Virus in people. J. Virol. 91, e01469–17 (2017).
Wragg, Ok. M. et al. Institution and recall of SARS-CoV-2 spike epitope-specific CD4(+) T cell reminiscence. Nat. Immunol. 23, 768–780 (2022).
Francis, J. M. et al. Allelic variation in school I HLA determines CD8(+) T cell repertoire form and cross-reactive reminiscence responses to SARS-CoV-2. Sci. Immunol. 7, eabk3070 (2022).
Heitmann, J. S. et al. A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity. Nature 601, 617–622 (2022).
Bastard, P. Why do folks die from COVID-19? Science 375, 829–830 (2022).
Minervina, A. A. et al. SARS-CoV-2 antigen publicity historical past shapes phenotypes and specificity of reminiscence CD8 T cells. medRxiv https://doi.org/10.1101/2021.07.12.21260227 (2022).
Choi, H. et al. Protecting immunity by an engineered DNA vaccine for Mayaro virus. PLoS Negl. Trop. Dis. 13, e0007042 (2019).
Vijgen, L. et al. Growth of one-step, real-time, quantitative reverse transcriptase PCR assays for absolute quantitation of human coronaviruses OC43 and 229E. J. Clin. Microbiol. 43, 5452–5456 (2005).
Mendoza, E. J., Manguiat, Ok., Wooden, H. & Drebot, M. Two detailed plaque assay protocols for the quantification of infectious SARS-CoV-2. Curr. Protoc. Microbiol. 57, ecpmc105 (2020).
Corman, V. M. et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 25, 2000045 (2020).
Alexandersen, S., Chamings, A. & Bhatta, T. R. SARS-CoV-2 genomic and subgenomic RNAs in diagnostic samples should not an indicator of lively replication. Nat. Commun. 11, 6059 (2020).
Elong Ngono, A. et al. Mapping and position of the CD8(+) T cell response throughout main Zika virus an infection in mice. Cell Host Microbe 21, 35–46 (2017).
Gruber, A. D. et al. Standardization of reporting standards for lung pathology in SARS-CoV-2-infected hamsters: what issues? Am. J. Respir. Cell Mol. Biol. 63, 856–859 (2020).
Alves, R. SOURCE_DATA_NCOMMS-23-38557B_part9 [Data set]. Zenodo https://doi.org/10.5281/zenodo.10397796, (2023).
